Galera Therapeutics, Inc.
GRTXOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$2.5M | −$20.2M | −$49.3M | −$51.2M | −$73.4M | −$70.6M |
| Net income | $149.0M | −$19.0M | −$59.1M | −$62.2M | −$80.5M | −$74.2M |
| Total assets | $7.2M | $10.1M | $26.1M | $44.0M | $83.3M | $84.1M |
| Total liabilities | $645,000 | $153.8M | $157.3M | $153.2M | $141.3M | $78.0M |
| Equity | $4.0M | −$148.0M | −$131.2M | −$109.2M | −$58.0M | $6.1M |
| EPS (diluted) | $0.64 | $-0.34 | $-1.33 | — | — | — |
| Shares out. | 75.5M | 54.4M | 42.8M | 26.8M | 25.0M | 24.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 3750.6%
- Return on assets
- 2071.3%
- Return on capital (ROCE)
- −38.8%
- Liabilities / assets
- 9.0%
- Debt / equity
- 0.16×
- Book value / share
- $0.05
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -129.25distress
- Accruals / assets
- 2155.3%high accruals
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Emerald Bioventures, LlcActivist (13D)May 29, 2026
- Chang Nancy TActivist (13D)Apr 10, 2026
- Ikarian Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Emerald Bioventures, Llc10% owner | May 15, 2026 | Conversion | 20.8M | — |
| Friedman Michael R.Director | Apr 7, 2026 | Conversion | 5.3M | — |
| Chang Nancy TDirector | Apr 7, 2026 | Conversion | 1.2M | — |
| Sorensen MelOfficer — President and CEO | Nov 20, 2025 | Sell | 70,000 | $0.02 |
| Chang Nancy TDirector | Dec 30, 2024 | Buy | 7.6M | $0.07 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6,719 | 1.0 | 0.0% |
| Apr 30, 2026 | 6,719 | 1.0 | -36.8% |
| Apr 15, 2026 | 10,629 | 1.0 | +58.2% |
| Mar 31, 2026 | 6,719 | 1.0 | 0.0% |
| Mar 13, 2026 | 6,719 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 19, 2026
- Amended charter or bylawsMay 15, 2026
- Shareholder voteMay 11, 2026
- Entered a material agreement · Unregistered equity sale · Change in control · Regulation FD disclosureApr 14, 2026
- Other material eventApr 9, 2026
- Other material eventApr 3, 2026
- Amended charter or bylawsFeb 18, 2026
- Director / officer changeFeb 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13D/AMay 29, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 29, 2026
- 425May 22, 2026
- 425May 21, 2026
- 8-KMay 19, 2026
- 8-KMay 15, 2026
- 10-QMay 14, 2026
- 8-KMay 11, 2026
- 3INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESMay 4, 2026
- SCHEDULE 13DApr 27, 2026
- 425Apr 22, 2026
- 425Apr 22, 2026
- ARSApr 20, 2026
- DEF 14AApr 20, 2026
- 425Apr 15, 2026